Beximco Pharmaceuticals PLC. announcements
297 Dhaka Stock Exchange announcements for Beximco Pharmaceuticals PLC. (BXPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (19).
- Credit Rating Result
Credit Rating Information and Services Limited (CRISL) has assigned the rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook in consideration of its audited financials up to June 30, 2024; unaudited financials up to September 30, 2024 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after Record date
Trading of the shares of the company will resume on 26.11.2024.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 25.11.2024.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 21.11.2024 to 24.11.2024 and trading of the shares will remain suspended on record date i.e., 25.11.2024.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 3.77 for July-September 2024 as against Tk. 3.48 for July-September 2023; Consolidated NOCFPS was Tk. 3.80 for July-September 2024 as against Tk. 6.07 for July-September 2023. Consolidated NAV per share was Tk. 111.25 as on September 30, 2024 and Tk. 101.40 as on September 30, 2023.
- Regarding dividend declaration of subsidiary companies
The company has informed that the Board of Directors of Nuvista Pharma Limited (NPL) recommended 50% cash dividend and the Board of Directors of Synovia Pharma PLC (SPP) recommended 10% cash dividend, two subsidiary companies of Beximco Pharmaceuticals Ltd., for the year 2023-24. The proposed dividends are subject to approval of the shareholders of the respective companies in the forthcoming annual general meeting.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2024 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- Dividend Declaration
The Board of Directors has recommended 40% Cash Dividend for the year ended June 30, 2024. Date of AGM: 29.12.2024, Time: 10:30 AM, Venue: Virtual Platform. Record Date: 25.11.2024. The Company has also reported consolidated EPS of Tk. 13.07, consolidated NAV per share of Tk. 107.48 and consolidated NOCFPS of Tk. 18.75 for the year ended June 30, 2024 as against Tk. 10.34, Tk. 97.91 and Tk. 13.64 respectively for the year ended June 30, 2023.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2024) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Query Response
In response to the DSE query dated August 27, 2024, the company has informed that they do not have any undisclosed material decision/information relating to the company's operation/profitability that might have impact on price fall of shares of the company.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 3.06 for January-March 2024 as against Tk. 2.13 for January-March 2023; Consolidated EPS was Tk. 9.75 for July 2023-March 2024 as against Tk. 8.15 for July 2022-March 2023. Consolidated NOCFPS was Tk. 14.79 for July 2023-March 2024 as against Tk. 9.66 for July 2022-March 2023. Consolidated NAV per share was Tk. 104.17 as on March 31, 2024 and Tk. 95.65 as on March 31, 2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2024 at 03:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
- Appointment of Managing Director
The Board of Directors of the Company has appointed the existing Director Mr. Iqbal Ahmed as the Managing Director of the Company for a period of 5 (Five) years effective from 03.03.2024 to 02.03.2029, subject to the approval of the Shareholders in the next Annual General Meeting (AGM) of the Company.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
- (Q2 Un-audited): Consolidated EPS was Tk. 3.21 for October-December 2023 as against Tk. 2.77 for October-December 2022;
(Q2 Un-audited): Consolidated EPS was Tk. 3.21 for October-December 2023 as against Tk. 2.77 for October-December 2022; Consolidated EPS was Tk. 6.69 for July-December 2023 as against Tk. 6.02 for July-December 2022. Consolidated NOCFPS was Tk. 10.01 for July-December 2023 as against Tk. 5.33 for July-December 2022. Consolidated NAV per share was Tk. 101.11 as on December 31, 2023 and Tk. 93.52 as on December 31, 2022. (cont.)
- Q2 Financials
(Continuation news of BXPHARMA): Reasons for deviation in NOCFPS: Cash outflows for inventories during comparable prior period were notably higher because of strategic buildup of inventories to protect against any supply chain disruption. This, together with improved working capital and revenue growth, resulted in a positive deviation in current period's Operating Cash Flows per share. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
- Managing Director Resigns to Join Newly Formed Cabinet
The company has announced that Mr. Nazmul Hassan MP, the company's Managing Director and Member of the Board, will step down with immediate effect. This follows an invitation from the Prime Minister for Mr. Hassan to join the newly formed Cabinet as a Minister after the recent Bangladesh Parliamentary Election on January 07, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.